Skip to main content

Table 2 ALK inhibitors in development

From: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

Chemical series Therapeutics Development stage
Aminopyridine PF-2341066 (crizotinib) Phase II/III: NSCLC; phase I/II: advanced solid tumors, neuroblastoma, and ALCL
Diaminopyrimidine CEP-28122 Preclinical
IND application expected
Structure undisclosed AP-26113 Preclinical
IND application expected in 2011
Structure undisclosed X-276 Preclinical
Pyridoisoquinoline F91873 and F91874 Preclinical
Pyrrolopyrazole PHA-E429 Preclinical
Indolocarbazole CEP-14083 and CEP-14513 Preclinical
No further development
Pyrrolopyrimidine GSK1838705A Preclinical
No further development
Dianilinopyrimidine NVP-TAE684 Preclinical
No further development
  1. NSCLC, non-small cell lung cancer; ALCL, anaplastic large cell lymphoma
  2. Reference [60, 61, 64, 65, 140150]